 Bicycle Therapeutics plc NASDAQ: BCYC announced that Ionis Pharmaceuticals Inc NASDAQ: IONS has exercised its option and entered into an exclusive worldwide license and collaboration agreement to develop oligonucleotide therapeutics. The agreement granted Ionis the right to evaluate tissue-targeting TfR1 binding Bicycles as vehicles to deliver oligonucleotide therapeutics to specific organ systems and an option to obtain an exclusive license at the end of the evaluation period. 